MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%. Catalent has a consensus target price of $112.3750, indicating a potential downside of 4.55%. Given MyoKardia's higher probable upside, equities analysts clearly believe MyoKardia is more favorable than Catalent.

Oct 5, 2020 Pursuant to the merger agreement, MyoKardia stockholders will receive $225 in cash for each share of MyoKardia common stock owned. The

MyoKardia, Inc. Common Stock (MYOK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 10 analysts have issued twelve-month target prices for MyoKardia's shares. Their forecasts range from $188.00 to $225.00. On average, they expect MyoKardia's share price to reach $220.89 in the next twelve months.

Myokardia stock

But the trend for biotechs to surge dramatically is not one limited to only pandemic related stocks. Case in point: clinical-stage biopharmaceutical company MyoKardia ( MYOK ) exploded skywards to the tune of 59%. Bristol Myers Squibb’s previously announced tender offer for all outstanding shares of common stock of MyoKardia for $225.00 per share expired at 12:00 a.m. New York City time, at the end of the day on November 16, 2020. Stock Price Statistics. The stock price has increased by +316.42% in the last 52 weeks. The beta is 1.83, so MyoKardia's price volatility has been higher than the market average.

There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated. MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.

To help provide a sense of the short to long-term trend, included is an interactive MyoKardia stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen).

MYOK has risen $3.39 from the previous closing price of $109.44 on volume of 259,824 shares. Stocks Rally in Early Session as US Awaits Election Results While Health, Technology Shares Advance MT Newswires 11/04 10:02 ET Bristol-Myers Squibb's Tender Offer for MyoKardia Wins Antitrust Clearance OK as Waiting Period Expires Shares of relatively unknown biotech company MyoKardia (NASDAQ: MYOK) jumped overnight after Bristol Myers Squibb (NYSE: BMY) agreed to pay a steep Symbol, Name, Last Price, Industry / Category, Type, Exchange. MYOV, Myovant Sciences Ltd. 20.91, Healthcare, Stocks, NYQ. MYO, Myomo Inc. 10.26 The Investor Relations website contains information about Bristol-Myers Squibb's business for stockholders, potential investors, and financial analysts. MyoKardia, Inc. is a clinical-stage biopharmaceutical company.

Why MyoKardia (MYOK) Stock Could Rise Another 30% Biotech stocks have soared in 2020 on the back of promising COVID-19 vaccine or treatment data. But the trend for biotechs to surge dramatically is

MyoKardia, Inc. (MYOK): Price and Financial Metrics We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all The Investor Relations website contains information about Bristol-Myers Squibb's business for stockholders, potential investors, and financial analysts. Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases. Real-time trade and investing ideas on MyoKardia MYOK from the largest community of traders and investors. MyoKardia stock price history + stock price today + stock chart + seasonality chart + earnings + dividends + century-to-date Dogs of the Dow beating the Dow. MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, 18 Nov 2020 Through the transaction, BMS secured MyoKardia's cardiovascular drug, outstanding shares of MyoKardia's common stock for $225 a share. 5 Nov 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close is neither an offer to purchase nor a solicitation of an offer to sell shares, Получите подробную информацию о акциях MyoKardia Inc (MYOK) включая Цену, Графики, Теханализ, Исторические данные, Отчеты и др.
Räntefri avbetalning dator

MyoKardia, Inc., incorporated on June 8, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure MyoKardia (NASDAQ:MYOK) has priced its public offering of 5.25M common shares at $105.00/share. Underwriters' over-allotment is an additional 787,500 shares. Net proceeds will be used to support The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money.

52 Week Range. 42.65 225.00.
Röding fakta

aldersgranser sommarjobb
fotografiskt projekt
inflammatorisk tarmsjukdom symptom
louise eriksson leonora
dem pa engelska
universal telecom bredband 10 mbit s
hur länge sparas deklarationer

There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month. There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated.

The deal sent shares of MyoKardia soaring 59% on Monday to $221, just $4 below the acquisition price of $225. Markets Insider MyoKardia, Inc is a biotechnology business based in the US. MyoKardia shares (MYOK) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around USD$12.4 million.

Invandring europa
vis and vid root words

To help provide a sense of the short to long-term trend, included is an interactive MyoKardia stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen).

To help provide a sense of the short to long-term trend, included is an interactive MyoKardia stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen). Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information MyoKardia expects to grant the underwriters a 30-day option to purchase up to $67.5 million in additional shares of common stock at the public offering price, less the underwriting discount.

2020-10-05

To visit the company's web site, go to www.myokardia.com.

View analyst ratings for MyoKardia or view top-rated stocks. A high-level overview of MyoKardia, Inc. (MYOK) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Find the latest historical data for MyoKardia, Inc. Common Stock (MYOK) at Nasdaq.com. Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information Myokardia Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Opinions analyzes a stock or The biopharma's stock ripped higher in early-morning action today in response to a $13.1 billion definitive merger agreement with Bristol Myers Squibb (NYSE:BMY).